



# MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

## Medical Policy Cardiovascular Risk Panels

### Table of Contents

- [Policy: Commercial](#)
- [Description](#)
- [Information Pertaining to All Policies](#)
- [Authorization Information](#)
- [Policy History](#)
- [References](#)
- [Coding Information](#)

### Policy Number: 664

BCBSA Reference Number: 2.04.100 (For Plan internal use only)

NCD/LCD: N/A

### Related Policies

- Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease and Venous Thromboembolic Disease, [#016](#)
- Measurement of Lipoprotein-Associated Phospholipase A2 in the Assessment of Cardiovascular Risk, [#558](#)
- Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease, [#283](#)
- Ultrasonographic Measurement of Carotid Intima-Medial Thickness as an Assessment of Subclinical Atherosclerosis, [#547](#)

### Policy

#### Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO Blue<sup>SM</sup> and Medicare PPO Blue<sup>SM</sup> Members

Cardiovascular disease risk panels, consisting of multiple individual biomarkers intended to assess cardiac risk, are [INVESTIGATIONAL](#).

### Prior Authorization Information

#### Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

#### Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	This is <b>not</b> a covered service.
Commercial PPO and Indemnity	This is <b>not</b> a covered service.
Medicare HMO Blue <sup>SM</sup>	This is <b>not</b> a covered service.
Medicare PPO Blue <sup>SM</sup>	This is <b>not</b> a covered service.

## CPT Codes / HCPCS Codes / ICD Codes

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*

*Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.*

### CPT Codes

No specific CPT codes

## Description

### Cardiovascular Disease

Cardiovascular disease (CVD) remains the single largest cause of morbidity and mortality in the developed world. As a result, accurate prediction of CVD risk is a component of medical care that has the potential to focus on and direct preventive and diagnostic activities. Current methods of risk prediction in use in general clinical care are not highly accurate and, as a result, there is a potential unmet need for improved risk prediction instruments.

### Risk Assessment

Components of CVD risk include family history, cigarette smoking, hypertension, and lifestyle factors such as diet and exercise. Also, numerous laboratory tests have been associated with CVD risk, most prominently lipids such as low-density lipoprotein (LDL) and high-density lipoprotein (HDL). These clinical and lipid factors are often combined into simple risk prediction instruments, such as the Framingham Risk Score.<sup>1</sup> The Framingham Risk Score provides an estimate of the 10-year risk for developing cardiac disease and is currently used in clinical care to determine the aggressiveness of risk factor intervention, such as the decision to treat hyperlipidemia with statins.

Many additional biomarkers, genetic factors, and radiologic measures have been associated with increased risk of CVD. Over 100 emerging risk factors have been proposed as useful for refining estimates of CVD risk.<sup>2,3,4</sup> Some general categories of these potential risk factors are as follows:

- **Lipid markers.** In addition to LDL and HDL, other lipid markers may have predictive ability, including the apolipoproteins, lipoprotein (a) (Lp[a]), lipid subfractions, and/or other measures.
- **Inflammatory markers.** Many measures of inflammation have been linked to the likelihood of CVD. High-sensitivity C-reactive protein (hs-CRP) is an example of an inflammatory marker; others include fibrinogen, interleukins, and tumor necrosis factor.
- **Metabolic syndrome biomarkers.** Measures associated with metabolic syndromes, such as specific dyslipidemic profiles or serum insulin levels, have been associated with an increased risk of CVD.
- **Genetic markers.** A number of variants associated with increased thrombosis risk, such as the 5,10-methylene tetrahydrofolate reductase (MTHFR) variant or the prothrombin gene variants, have been associated with increased CVD risk. Also, numerous single nucleotide variants have been associated with CVD in large genome-wide studies.

### Risk Panel Testing

Cardiovascular disease risk panels may contain measures from 1 or all of the previous categories and may include other measures not previously listed such as radiologic markers (carotid medial thickness, coronary artery calcium score). Some CVD risk panels are relatively limited, including a few markers in addition to standard lipids. Others include a wide variety of potential risk factors from a number of different categories, often including both genetic and nongenetic risk factors. Other panels are composed entirely of genetic markers.

Some examples of commercially available CVD risk panels are as follows:

- **CV Health Plus Genomics™ Panel (Genova Diagnostics):** apolipoprotein (apo) E; prothrombin; factor V Leiden; fibrinogen; HDL; HDL size; HDL particle number; homocysteine; LDL; LDL size; LDL

particle number; Lp(a); lipoprotein-associated phospholipase A2 (Lp-PLA2); *MTHFR* gene; triglycerides; very-low-density lipoprotein (VLDL); VLDL size; vitamin D; hs-CRP.

- **CV Health Plus™ Panel (Genova Diagnostics):** fibrinogen; HDL; HDL size; HDL particle number; homocysteine; LDL; LDL size; LDL particle number; lipid panel; Lp(a); Lp-PLA2; triglycerides; VLDL; VLDL size; vitamin D; hs-CRP.
- **CVD Inflammatory Profile (Cleveland HeartLab):** hs-CRP, urinary microalbumin, myeloperoxidase, Lp-PLA2, F<sub>2</sub> isoprostanes.
- **Applied Genetics Cardiac Panel:** genetic variants associated with coronary artery disease: cytochrome p450 variants associated with the metabolism of clopidogrel, ticagrelor, warfarin, b-blockers, rivaroxaban, prasugrel (2C19, 2C9/VKORC1, 2D6, 3A4/3A5), factor V Leiden, prothrombin gene, *MTHFR* gene, *APOE* gene.
- **Genetiks Genetic Diagnosis and Research Center Cardiovascular Risk Panel:** factor V Leiden, factor V R2, prothrombin gene, factor XIII, fibrinogen-455, plasminogen activator inhibitor-1, platelet glycoprotein (GP) IIIA variant human platelet antigen (HPA)-1 (PLA1/2), *MTHFR* gene, angiotensin-converting enzyme insertion/deletion, apo B, apo E.

In addition to panels that are specifically focused on CVD risk, a number of commercially available panels include markers associated with cardiovascular health, along with a range of other markers that have been associated with inflammation, thyroid disorders and other hormonal deficiencies, and other disorders. An example of these panels is:

- **WellnessFX Premium (WellnessFX):** total cholesterol, HDL, LDL, triglycerides, apo AI, apo B, Lp(a), Lp-PLA2, omega-3 fatty acids, free fatty acids, lipid particle numbers, lipid particle sizes, blood urea nitrogen/creatinine, aspartate aminotransferase and alanine aminotransferase, total bilirubin, albumin, total protein, dehydroepiandrosterone, free testosterone, total testosterone, estradiol, sex hormone binding globulin, cortisol, insulin-like growth factor 1, insulin, glucose, hemoglobin A1c, total T4, T3 uptake, free T4 index, thyroid-stimulating hormone, total T3, free T3, reverse T3, free T4, hs-CRP, fibrinogen, homocysteine, complete blood count with differential, calcium, electrolytes, bicarbonate, ferritin, total iron-binding capacity, vitamin B12, red blood cell magnesium, 25-hydroxy vitamin D, progesterone, follicle-stimulating hormone, luteinizing hormone.<sup>5</sup>

## Summary

Cardiovascular risk panels refer to different combinations of cardiac markers that are intended to evaluate the risk of cardiovascular disease (CVD). There are numerous commercially available risk panels that include different combinations of lipids, noncardiac biomarkers, measures of inflammation, metabolic parameters, and/or genetic markers. Risk panels report the results of multiple individual tests, as distinguished from quantitative risk scores that combine the results of multiple markers into a single score.

## Summary of Evidence

For individuals who have risk factors for CVD who receive CVD risk panels, the evidence includes multiple cohorts and case-control studies and systematic reviews of these studies.

Relevant outcomes are test validity, other test performance measures, change in disease status, and morbid events. The available evidence from cohort and case-control studies indicates that many of the individual risk factors included in CVD risk panels are associated with increased risk of CVD. However, it is not clear how the results of individual risk factors impact management changes, so it is also uncertain how the panels will impact management decisions. Given the lack of evidence for the clinical utility of any individual risk factor beyond simple lipid measures, it is unlikely that the use of CVD risk panels improves outcomes. Studies that have evaluated the clinical validity of panels of multiple markers have not assessed management changes that would occur as a result of testing or demonstrated improvements in outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## Policy History

Date	Action
2/2022	Annual policy review. Description, summary, and references updated. Policy statements unchanged.

2/2021	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2020	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
2/2019	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
3/2018	Annual policy review. New references added.
1/2016	Annual policy review. New references added.
12/2014	Annual policy review. New references added.
4/2014	New medical policy describing investigational indications. Effective 4/1/2014.

## Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

## References

1. D'Agostino RB, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. *JAMA*. Jul 11 2001; 286(2): 180-7. PMID 11448281
2. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. *Ann Intern Med*. Oct 06 2009; 151(7): 496-507. PMID 19805772
3. Brotman DJ, Walker E, Lauer MS, et al. In search of fewer independent risk factors. *Arch Intern Med*. Jan 24 2005; 165(2): 138-45. PMID 15668358
4. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. Dec 14 2010; 56(25): e50-103. PMID 21144964
5. WellnessFX. Premium: The Deluxe Deep Dive. n.d.; <https://www.wellnessfx.com/premium>. Accessed November 11, 2021.
6. van Holten TC, Waanders LF, de Groot PG, et al. Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. *PLoS One*. 2013; 8(4): e62080. PMID 23630624
7. Gottlieb SS, Harris K, Todd J, et al. Prognostic significance of active and modified forms of endothelin 1 in patients with heart failure with reduced ejection fraction. *Clin Biochem*. Mar 2015; 48(4-5): 292-6. PMID 25541019
8. Patterson CC, Blankenberg S, Ben-Shlomo Y, et al. Which biomarkers are predictive specifically for cardiovascular or for non-cardiovascular mortality in men? Evidence from the Caerphilly Prospective Study (CaPS). *Int J Cardiol*. Dec 15 2015; 201: 113-8. PMID 26298350
9. Malachias MVB, Jhund PS, Claggett BL, et al. NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus. *J Am Heart Assoc*. Oct 20 2020; 9(19): e017462. PMID 32964800
10. Schoe A, Schippers EF, Ebmeyer S, et al. Predicting mortality and morbidity after elective cardiac surgery using vasoactive and inflammatory biomarkers with and without the EuroSCORE model. *Chest*. Nov 2014; 146(5): 1310-1318. PMID 24992322
11. Wallentin L, Eriksson N, Olszowka M, et al. Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. *PLoS Med*. Jan 2021; 18(1): e1003513. PMID 33439866
12. Wuopio J, Hilden J, Bring C, et al. Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study. *Atherosclerosis*. Nov 2018; 278: 97-102. PMID 30261474

13. Winkel P, Jakobsen JC, Hilden J, et al. Prognostic value of 12 novel cardiological biomarkers in stable coronary artery disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial. *BMJ Open*. Aug 20 2020; 10(8): e033720. PMID 32819979
14. Welsh P, Kou L, Yu C, et al. Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. *Eur J Heart Fail*. Feb 2018; 20(2): 268-277. PMID 28960777
15. Harari G, Green MS, Magid A, et al. Usefulness of Non-High-Density Lipoprotein Cholesterol as a Predictor of Cardiovascular Disease Mortality in Men in 22-Year Follow-Up. *Am J Cardiol*. Apr 15 2017; 119(8): 1193-1198. PMID 28267961
16. Kunutsor SK, Bakker SJ, James RW, et al. Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies. *Atherosclerosis*. Feb 2016; 245: 143-54. PMID 26724525
17. Di Angelantonio E, Gao P, Pennells L, et al. Lipid-related markers and cardiovascular disease prediction. *JAMA*. Jun 20 2012; 307(23): 2499-506. PMID 22797450
18. Keller T, Boeckel JN, Gross S, et al. Improved risk stratification in prevention by use of a panel of selected circulating microRNAs. *Sci Rep*. Jul 03 2017; 7(1): 4511. PMID 28674420
19. de Lemos JA, Ayers CR, Levine BD, et al. Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts. *Circulation*. May 30 2017; 135(22): 2119-2132. PMID 28360032
20. Greisenegger S, Segal HC, Burgess AI, et al. Biomarkers and mortality after transient ischemic attack and minor ischemic stroke: population-based study. *Stroke*. Mar 2015; 46(3): 659-66. PMID 25649803
21. Cho S, Lee SH, Park S, et al. The additive value of multiple biomarkers in prediction of premature coronary artery disease. *Acta Cardiol*. Apr 2015; 70(2): 205-10. PMID 26148381
22. Wilsgaard T, Mathiesen EB, Patwardhan A, et al. Clinically significant novel biomarkers for prediction of first ever myocardial infarction: the Tromso Study. *Circ Cardiovasc Genet*. Apr 2015; 8(2): 363-71. PMID 25613532
23. Guarrera S, Fiorito G, Onland-Moret NC, et al. Gene-specific DNA methylation profiles and LINE-1 hypomethylation are associated with myocardial infarction risk. *Clin Epigenetics*. 2015; 7: 133. PMID 26705428
24. Lara J, Cooper R, Nissan J, et al. A proposed panel of biomarkers of healthy ageing. *BMC Med*. Sep 15 2015; 13: 222. PMID 26373927
25. Paynter NP, Chasman DI, Pare G, et al. Association between a literature-based genetic risk score and cardiovascular events in women. *JAMA*. Feb 17 2010; 303(7): 631-7. PMID 20159871
26. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *JAMA*. Feb 14 2007; 297(6): 611-9. PMID 17299196
27. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. *N Engl J Med*. May 15 2008; 358(20): 2107-16. PMID 18480203
28. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. Jun 24 2014; 129(25 Suppl 2): S49-73. PMID 24222018
29. Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology. *Circulation*. Jun 18 2019; 139(25): e1162-e1177. PMID 30586766
30. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. Jan 01 2020; 41(1): 111-188. PMID 31504418
31. U.S. Preventive Services Task Force. Cardiovascular disease: risk assessment with nontraditional risk factors. 2018; <https://www.uspreventiveservicestaskforce.org/Page/Document/final-evidence-summary--html/cardiovascular-disease-screening-using-nontraditional-risk-assessment>. Accessed November 11, 2021.